# A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

> **NCT06150664** · PHASE1 · RECRUITING · sponsor: **Compass Therapeutics** · enrollment: 85 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Triple Negative Breast Cancer
- Hodgkin Lymphoma
- Head and Neck Squamous Cell Carcinoma
- Malignant Melanoma

## Interventions

- **DRUG:** CTX-8371

## Key facts

- **NCT ID:** NCT06150664
- **Lead sponsor:** Compass Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-19
- **Primary completion:** 2026-12
- **Final completion:** 2027-05
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06150664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06150664, "A Phase 1 of CTX-8371 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06150664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*